Nurses' and pharmacists' exposure to antineoplastic drugs: Findings from industrial hygiene scans and urine mutagenicity tests

Cancer Nursing

Volumn 21, Issue 2, 1998, Pages 79-89

  Labuhn, Karen ^a   Valanis, Barbara ^b,e   Schoeny, Rita ^c   Loveday, Kenneth ^d   Vollmer, William M ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b KAISER PERMANENTE   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d Creative Bio Molecules ^*  (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Antineoplastic drugs; Industrial hygiene; Mutagenesis; Occupational exposures

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BLEOMYCIN SULFATE; CARBOPLATIN; CARMUSTINE; CHLORMETHINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; IMIDAZOLE; MITHRAMYCIN; MITOMYCIN C; MITOXANTRONE; THIOTEPA; VINBLASTINE; VINCRISTINE; VINLEUROSINE;

ADULT; ARTICLE; CONTAMINATION; DRUG EXPOSURE; FEMALE; HUMAN; INDUSTRIAL HYGIENE; MAJOR CLINICAL STUDY; MALE; MUTAGEN TESTING; MUTAGENICITY; NURSE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PHARMACIST; PRIORITY JOURNAL; SKIN PROTECTION; URINALYSIS;

ADULT; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTAGENICITY TESTS; NURSES; OCCUPATIONAL EXPOSURE; PHARMACISTS; STATISTICS, NONPARAMETRIC; UNITED STATES;

EID: 0031980255     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-199804000-00001     Document Type: Article

References (39)

1. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, Vol 26. Lyon: International Agency for Research on Cancer, 1981:192.
2. Sieber SM, Adamson RH. Toxicity of antineoplastic agents in man: chromosomal aberrations, antifertility effects, congenital malformations, and carcinogenic potential. Adv Cancer Res 1975;22:57-155.
3. Weisburger JH, Griswold DP, Prejean JD, Casey AE, Wood HB, Weisburger EK. The carcinogenic properties of some of the principal drugs used in clinical cancer chemotherapy. Recent Results Cancer Res 1975;52:1-17.
4. Occupational Safety and Health Administration (OSHA). Work practice guidelines for personnel dealing with cytotoxic (cytotoxic) drugs (OSHA Instruction Publication 8-1.1). Washington, DC: Office of Occupational Medicine, U.S. Department of Labor, 1986.
5. Christensen CJ, Lemasters GK, Wakeman MA. Work practices and policies of hospital pharmacists preparing antineoplastic agents. J Occup Med 1990;32:508-12.
6. Cohen IA, Newland SJ, Kirking DM. Injectable-antineoplasitic-drug practices in Michigan hospitals. Am J Hosp Pharm 1987;44: 1096-1106.
7. Niewig RM, deBoer M, Dubbleman RC, Gall HE, Hesselman GM, Lenssen PC, VanMaanen LW, Jajoor PW, Ouwerkerk J, Slegt JH. Safe handling of antineoplastic drugs: results of a survey. Cancer Nurs 1994;17:6, 501-11.
8. Valanis B, McNeil V, Driscoll K, Staff members' compliance with their facility's antineoplastic drug handling policy. Oncol Nurs Forum 1991;18:3, 571-6.
9. Valanis B, Shortridge L. Self-protective practices of nurses handling antineoplastic drugs in various health care settings. Oncol Nurs Forum 1987;14:23-7.
10. Valanis B, Vollmer W, Labuhn K, Glass A, Corelle C. Antineoplastic drug handling protection after OSHA guidelines: comparison by profession, handling activity, and work site. J Occup Med 1992;34:2, 149-55.
11. Wiseman KC, Wachs JE. Policies and practices used for the safe handling of antineoplastic drugs. AAOHN J 1990;38:11, 517-23.
12. Kleinberg ML, Quinn MJ. Airborne drug levels in a laminar-flow hood. Am J Hosp Pharmacy 1981;38:1301-3.
13. Neal AD, Wadden RA, Chiou WL. Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm 1983;40:597-601.
14. VanRaalte J, Rice C, Moss CE. Visible-light system for detecting doxorubicin contamination on skin and surfaces. Am J Hosp Pharm 1990;47:1067-74.
15. Vainio H. Current trends in the biological monitoring of exposure to carcinogens. Scand J Work Environ Health 1985;11:1-6.
16. Valanis B. Environmental and direct measures of exposure. Occup Med 1986;1:3, 431-44.
17. Newman MA, Valanis BG, Schoeny RS, Hee SQ. Urinary biological monitoring markers of anticancer drug exposure in oncology nurses. Am J Public Health 1994:84:5, 852-5.
18. Nguyen TV, Theiss JC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res 1982;42:4792-6.
19. Anderson RW, Puckett WH, Dana WJ, Nguyen TV, Theiss JC, Matney TS. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982;39:1881-7.
20. Connor TH, Theiss JC, Anderson RW, Puckett WH, Matney TS. Reevaluation of urine mutagenicity of pharmacy personnel exposed to antineoplastic agents. Am J Hosp Pharm 1986;43:1236-9.
21. Tuffnell PG, Gannon MT, Dong A, Deboer G, Erlichman C. Limitations of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs. Am J Hosp Pharm 1986;43:2, 344-8.
22. Stucker I, Hirsch A, Doloy T, et al. Urine mutagenicity, chromosomal abnormalities, and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health 1986;57:195-205.
23. Boos R, Leenaars A, Theuws J, Henderson PT. Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Int Arch Occup Environ Health 1982;50:359-69.
24. Everson RB, Ratcliffe JM, Flack PM, Hoffman DM, Watanabe AS. Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures. Cancer Res 1985;45:6487-97.
25. Falck K, Grohn P, Sorsa M, et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979;1:1250-1.
26. Venitt S, Crofton-Sleigh C, Hunt J, Speechley V, Briggs, K, Monitoring of exposure of nursing and pharmacy personnel to cytostatic drugs: urinary mutation assays and urinary platinum as markers of absorption. Lancet 1984;1:74-7.
27. Baker R, Arlauskas A, Bonin A, Angus D. Detection of mutagenic activity in human urine following fried pork or bacon meals. Cancer Lett 1982;16:81-9.
28. Sousa J, Nath J, Ong T. Detection of urinary mutagenic activity following a fried beef meal. Environ Mutagen 1984;6:163.
29. Labuhn KT, Valanis BG, Glass AC, Vollmer WM. Implementing a cancer-control study in a National Cancer Institute clinical trials network. Cancer Pract 1994;2:1, 47-54.
30. Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the salmonella/mammalian-microsome mutagenicity test. Mutat Res 1975;31:347-64.
31. Kolmodin-Hedman B, Hartveg P, Soursa M, Falck K. Occupational handling of cytostatic drugs. Arch Toxicol 1983;52:25-33.
32. Valanis B, Vollmer W, Labuhn K, Glass A. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993a;50:455-62.
33. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs 1993b;16:4, 288-95
34. Minnich V, Smith ME, Thompson D, Kornfeld S. Detection of mutagenic activity in human urine using mutant strains of Salmonella typhimurium. Cancer 1976;38:1253-8.
35. Waters MD, Stack HF, Garrett NE, Jackson MA. The genetic activity profile database. Environ Health Perspect 1991;96:41-5.
36. Babrudi, Pani NB, Tamaro M, Monti-Bragadin C, Zunino F. Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells. Br J Cancer 1984;50:91-6.
37. Matney TS, Nguyen TV, Conner TH, Dana WJ, Theiss JG. Genotoxic classification of anticancer drugs. Teratog Carcinog Mutagen 1985;5: 319-28.
38. Seino Y, Nagao M, Yahagi T, Hoshi A, Kawachi T, Sugimura T. Mutagenicity of several classes of antitumor agents to Salmonella typhimurium TA98, TA 100, and TA92. Cancer Res 1978;38:2148-56.
39. Bartoli-Klugmann F, Pani B, Barbrudi N, Montibragadin C, Tamaro M, Venturin S. In vitro mutagenic activity of 5-(3,3-dimethyl-1-tiazenoj-imidizole-4-carboxamide (DTIC) in eukaryotic and prokaryotic cells. Carcinogenesis 1982;5:467-71.